Cancer intelligence company, C2i Genomics, will partner with with Karkinos Healthcare, a technology-led managed-care platform for cancer, to co-develop the MRD market in India. This partnership will mark India’s first whole-genome-sequencing (WGS) MRD test, and will expand MRD monitoring within the Karkino’s health system and its partners using the C2i Genomics ultrasensitive whole-genome analysis.
The recently CE-marked C2inform MRD test enables physicians to trace small amounts of persistent or recurrent cancer much earlier and at far lower levels than currently available technologies, the company reports. Its SaaS solution uses a cloud-based platform to perform cancer tumor burden monitoring on a global scale, utilizing equipped labs and sequencing networks worldwide. By using machine learning and AI technology to analyze patients’ blood for early detection of cancer recurrence or resistance, the company’s products allow for more informed treatment decisions and personalized treatment plans.
Through the partnership with Karkinos, the MRD test will be available through its Advanced Center for Cancer Diagnostics and Research at Kochi.
“Since founding C2i Genomics our team has been laser-focused on making sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the world, regardless of where patients or clinical trials are located,” said Asaf Zviran, CEO and co-founder of New York, NY-based C2i Genomics, in prepared remarks. “Karkinos Healthcare shares in our vision to increase access to distributed cancer monitoring and will be instrumental in advancing our commercialization efforts to bring the C2inform MRD test to labs across India.”
C2i Genomics launched its C2inform MRD test across Europe in April after snagging CE-IVD marking in the European Union, the United Kingdom, and Switzerland. The company has also completed several clinical trials across the globe, including cancer centers in Europe, the United States, and Singapore.
C2inform test works by applying whole-genome sequencing and artificial intelligence to just a 3-4mL blood sample to support rapid and accurate detection of cancer, monitor disease progression, and evaluate therapeutic efficacy. The test enables informed and timely personalized treatment decisions and supports the development of more effective cancer treatments through pharma drug development partnerships. The test requires significantly reduced lab operation complexity, eliminates the need to develop a patient-specific assay, and offers a rapid and high throughput solution for cancer patients across the EU.